Changes to Genetic Items on the MBS

From 1 November 2023, the following changes have been made to genetic pathology services items.  Details of the changes can be found by searching for the relevant item number at

    • Introduce pathology items 73437, 73438 and 73439, which allow testing for genetic variants in patients with non-squamous non-small cell lung carcinoma to be performed as a pathologist-determinable service;
    • A fee increase for item 73418 for genetic testing for cardiac arrhythmias;
    • New items 73440, 73441, 73442, 73443 and 73444 will be introduced for genetic testing for childhood hearing loss;
    • New items 73445, 73446, 73447 and 73448 will be introduced for gene panel testing for haematological malignancies;
    • New items 73451 and 73452 will be introduced for genetic testing to determine carrier status of cystic fibrosis, spinal muscular atrophy, and fragile X syndrome in patients who are planning pregnancy or already pregnant, and their reproductive partner;
    • New items 73453, 73454 and 73455 will be introduced for reproductive carrier testing for specific genetic variants that cause nine severe conditions commonly found in the Ashkenazi Jewish population, with testing available to individuals of reproductive age who identify as being of Ashkenazi Jewish decent;
    • New items 73456, 73457, 73458, 73459, 73460, 73461 and 73462 will introduced for the diagnosis of mitochondrial disease in patients who are suspected of having either acute or chronic diseases, and the cascade testing of their biological relatives;
    • New items 71202 and 73310 will be introduced for the detection of measurable residual disease (MRD) in patients with acute lymphoblastic leukaemia using flow cytometry and next-generation sequencing methods;
    • New item 73306 will be introduced for the EndoPredict brand gene expression profiling test, which is a genetic test that looks at expression levels of several genes that can be involved in breast cancer;
    • Amendments to item 73296 and 73297 to expand the eligible patient population which can access testing of genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer.